BioCentury

Current Editions

Venture report: Liquidity coming for Boundless’ syndicate; plus Avenzo’s $150M round

As VC-backed start-ups continue to watch and wait for their IPO window, a large syndicate backs an oncology start-up with aspirations to go public

Finance

Emerging Company Profile

Vandria: renewing mitochondria to treat CNS, muscle and other diseases

Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment

Data Byte

Eight PDUFA dates on deck in April

J&J and Legend’s CAR T therapy could move into earlier lines; Day One could get its first marketed product

Management Tracks

George Eliades at the helm of Mythic

Plus: Michael Lenardo to become CSO at Calico, and updates from Aveo and Dyadic

BioCentury ISSN 1097-7201